A Long-term, Continued Treatment and Follow-up Study in Subjects With Hematologic Malignancies Treated With Duvelisib (IPI-145)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Aug 2017
At a glance
- Drugs Duvelisib (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- Sponsors Infinity Pharmaceuticals
- 28 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Mar 2016 Status changed from planning to recruiting as reported by ClinicalTrials.gov.
- 17 Jan 2013 New trial record